Physician profile
Christopher T Snow
NPI 1336589712
$3,728.70
in general payments reported to CMS, 2019-2025
21 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $699 · 2020: $444 · 2021: $639 · 2022: $555 · 2023: $415 · 2024: $599 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $986.61 | 2019-2025 | Rocklatan, Precision 7, Precision7 |
| Coopervision INC. | $416.60 | 2019-2025 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $351.17 | 2022-2025 | Xiidra, Miebo, Infuse |
| Johnson & Johnson Vision Care, INC. | $340.17 | 2019-2025 | Acuvue |
| Novartis Pharmaceuticals Corporation | $321.72 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $292.02 | 2022-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $215.44 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $191.38 | 2020-2024 | Lipiflow System Activator (Disposable) |
| Allergan, INC. | $189.00 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $77.33 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $63.32 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $56.92 | 2023 | Acthar |
| Lkc Technologies, INC. | $42.05 | 2024 | |
| Thea Pharma INC. | $35.55 | 2024 | Iyuzeh |
| Shire North American Group INC | $29.39 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26.40 | 2025 | |
| Biotissue Holdings INC. | $23.33 | 2025 | |
| Oyster Point Pharma, INC. | $22.11 | 2025 | Tyrvaya |
| Dompe US, INC. | $17.36 | 2023 | Oxervate |
| Maculogix, INC. | $15.70 | 2019-2021 | |
| Rxsight INC | $15.13 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.